Intraperitoneal radioimmunotherapy for refractory epithelial ovarian cancer with 177Lu-CC49

Minerva Biotecnologica

Volumn 10, Issue 3, 1998, Pages 100-107

  Meredith, Ruby ^a,b   Alvarez, Ronald ^a   Khazaeli, M B ^a   Lo Buglio, Albert ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NONE   (United States)

Author keywords

Ovarian neoplasms; Radioimmunotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LUTETIUM; MONOCLONAL ANTIBODY; PACLITAXEL; RECOMBINANT INTERFERON;

ARTICLE; BONE MARROW TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; ISOTOPE LABELING; LAPAROTOMY; OVARY CANCER; PERITONEUM; RADIOIMMUNOTHERAPY; SALVAGE THERAPY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032322612     PISSN: 11204826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. McGuire W, Hoskins W, Brady M, Kucera P, Partridge E, Look K, Clarke-Pearson D. Comparison of Combination Therapy with Paclitaxel and Cisplatin versus Cyclophosphamide and Cisplatin in Patients with Suboptimal Stage III and IV Ovarian Cancer: A Gynecologic Oncology Group study. Semin Oncol 1997; 24(Suppl):S2-13-S2-16.
2. Roland P, Barnes MN, Niwas S, Robertson MW, Alvarez RD, Austin JM, Kilgore LC, Partridge EE. Response to Salvage Treatment in Recurrent Ovarian Cancer Treated Initially with Paclitaxel and Platinum-Based Combination Regimens. Gynecol Oncol 1998; 68:178-82.
3. Markman M, Reichman B, Hakest B, Rubin S, Lewis J, Jones W et al. Evidence Supporting the Superiority of Intraperitoneal Cisplatin compared to Intraperitoneal Carboplatin for Salvage Therapy of Small-volume Residual Ovarian Cancer. Gynecol Oncol 1993; 50:100-4.
4. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis J et al. Phase I Trial of Intraperitoneal Taxol: A Gynecologic Oncology Group Study. J Clin Oncol 1992;10:1485-91.
5. Markman M, Reichman B, Hakes T, Curtin J, Jones W, Lewis J et al. Intraperitoneal Chemotherapy in the Management of Ovarian Cancer. Cancer 1993;71(Suppl 4):1565-70.
6. McClay E, Braly P, Kirmani S, Plaxe S, McClay M, Wilgus L et al. Phase I Trial of Intraperitoneal Carboplatin and Etoposide with Granulocyte Macrophage Colony Stimulating Factor Support in Patients with Intraabdominal Malignancies. Cancer 1994;74:664-9.
7. Rowinsky FE, Hakes T et al. Phase I Trial of Weekly Intraperitoneal Taxol in Patients with Residual Ovarian Carcinoma: A GOG Study. Proc Am Soc Clin Oncol 1993;12:257.
8. Morgan DFL, Marcus R, Mendenhall W, Sombeck M, Freeman D, Million R. Stage III Ovarian Carcinoma: an Analysis of Treatment Results and Complications following Hyperfractionated Abdominopelvic Irradiation for Salvage. Int J Radiat Oncol Biol Phys 1994;29:169-76.
9. Hird V, Maraveyas A, Snook D, Dhokia B, Soutter W, Meares C et al. Epenetos. Adjuvant Therapy of Ovarian Cancer with Radioactive Monoclonal Antibody. Br J Cancer 1993;68:403-6.
10. Alberts DS, Liu PY, Hanningan EV, O'Toole R, Williams SD, Young JA et al. Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide Versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer. N Engl J Med 1996;335: 1950-5.
11. Varia M, Currie J, Benda J. Evaluation of Intraperitoneal Chromic Phosphate Suspension Therapy following Negative Second look Laparotomy for Epithelial Ovarian Carcinomas (Stage III) Phase III. GOG #93, Closed 10/96.
12. Hird V, Snook D, Kosmas C, Dhokia B, Stewart S, Mason P et al. Epenetos. Intraperitoneal Radioimmunotherapy with Yttrium-90-labeled Immunoconjugates. In: A. Epenetos, editor. Monoclonal Antibodies: Applications in Clinical Oncology. London: Chapman Hall 1991:267-71.
13. Meredith R, Bueschen A, Khazaeli M, Plott W, Grizzle W, Wheeler R et al. Treatment of Prostate Carcinoma with Radiolabeled Antibody CC49. J Nucl Med 1994;35:1017-22.
14. 131I-Labeled Monoclonal Antibody Therapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 1996;2:1811-8.
15. 131I-labeled Monoclonal Antibody OC125. Gynecol Oncol 1992;45:265-72.
16. Jacobs AJ, Fer M, Su FM, Breitz H, Thompson J, Goosgold H et al. Phase I Trial of a Rhenium 186-labeled Monoclonal Antibody Administered Intraperitoneally in Ovarian Carcinoma: Toxicity and Clinical Response. Obstet Gynecol 1993;82:586-93.
17. Epenetos A, Munro A, Stewart S, Rampling R, Lambert H, McKenzie C et al. Antibody-guided Irradiation of Advanced Ovarian Cancer with Intraperitoneally Administered Radiolabeled Monoclonal Antibodies. J Clin Oncol 1987;5(12):1890-9.
18. 131I-labeled B72.3 Monoclonal Antibody. Radiology 1988;167:35-40.
19. Larson S, Carrasquillo J, Colcher D, Yokoyama K, Reynolds J, Bacharach S et al. Estimates of Radiation Absorbed Dose for Intraperitoneally Administered Iodine-131 Radiolabeled B72.3 Monoclonal Antibody in Patients with Peritoneal Carcinomatoses. J Nucl Med 1991;32:1661-7.
20. Ward B, Mather S, Hawkins L, Crowther M, Shepard J, Granowska M et al. Localization of Radioiodine Conjugated to the Monoclonal Antibody HMFG2 in Human Ovarian Carcinoma: Assessment of Intravenous and Intraperitoneal Routes of Administration. Cancer Res 1987;47:4719-23.
21. Chatal J, Saccavini J, Gestin J, Thedrez P, Curtet C, Kremer M et al. Biodistribution of Indium-111-labeled OC 125 Monoclonal Antibody Intraperitoneally Injected into Patients Operated on for Ovarian Carcinomas. Cancer Res 1989;49:3087-94.
22. Colcher D, Esteban J, Carrasquillo J. Complementation of Intracavitary and Intravenous Administration of a Monoclonal Antibody B72.3 in Patients with Carcinoma. Cancer Res 1987; 47:4218-24.
23. Horan-Hand P, Shivastav S, Colcher D, Snoy P, Schlom J. Pharmacokinetics of Radiolabeled Monoclonal Antibodies following Intraperitoneal and Intravenous Administration in Rodents, Monkeys and Humans. Antib Immunoconj Radiopharm 1989;2:241-55.
24. 177Lutetium labeled Immunoconjugate. Cancer Res 1991;51:2889-96.
25. 177Lutetium-CC49. J Nucl Med 1996;37:1491-6.
26. 177Lu-CC49: A phase I/II Study. Gynecol Oncol 1997;65:94-101.
27. 177Lu-CC49. Proc. 6th Intl Radiopharm Dosimetry Symp, In press.
28. Murray JL, Macey DJ, Grant EJ, Rosenblum MG, Kasi LP, Zhang HZ. Podoloff. Enhanced TAG-72 Expression and Tumor Uptake of Radiolabeled Monoclonal Antibody CC49 in Metastatic Breast Cancer Patients following alpha-Interferon Treatment. Cancer Res 1995;55(Suppl):5925s-5928s.
29. 131I-labeled CC49: Outcomes in Patients with Androgen-independent Prostate Cancer. Clin Cancer Res 1998;4:643-51.
30. 131I-labeled Monoclonal Antibody CC49 in Breast Cancer: a Phase I Trial. Clin Cancer Res 1996;3:1547-55.
31. Guadagni F, Schlom J, Johnston WW, Szpak CA, Goldstein D, Smalley R et al. Selective Interferon-induced Enhancement of Tumor-associated Antigens on a Spectrum of Freshly Isolated Human Adenocarcinoma Cells. J Natl Cancer Inst 1989;81:502-12.
32. Van XW, Wong JY, Esteban JM, Kuhn JA, Beatty BG, Beatty JD et al. Effects of Recombinant Human Gamma-interferon on Carcinoembryonic Antigen Expression of Human Colon Cancer Cells. J Immunother 1992;11:77-84.
33. 131I-CC49) when given in Combination with Gamma-interferon. Cancer Res 1993;53:600-8.
34. Greiner JW, Guadagni F, Goldstein D, Borden EC, Ritts RE jr, Witt P et al. Evidence for the Elevation of Serum Carcinoembryonic Antigen and Tumor-Associated Glycoprotein-72 levels in Patients Administered Interferons. Cancer Res 1991;51:4155-63.
35. Greiner JW, Smalley RV, Borden EC, Martin EW, Guadagni F, Roselli M et al. Applications of Monoclonal Antibodies and Recombinant Cytokines for the Treatment of Human Colorectal and other Carcinomas. [Review] J Surg Oncol 1991;2(Suppl):9-13.
36. Roselli M, Guadagni F, Buonomo O, Belardi A, Vittorini V, Mariani-Costantini R et al. Systemic Administration of Recombinant Interferon Alfa in Carcinoma Patients Upregulates the Expression of the Carcinoma-associated Antigens Tumor-associated Glycoprotein-72 and Carcinoembryonic Antigen. J Clin Oncol 1996;14:2031-42.
37. Hei T, Piao C, Geard C, Hall E. Taxol and Ionizing Radiation: Interaction and Mechanisms. Int J Radiat Oncol Biol Phys 1994;29:267-71.
38. Milas L, Hunter N, Mason K, Kurdoglu B, Peters L. Enhancement of Tumor Radioresponse of a Murine Mammary Carcinoma by Paclitaxel. Cancer Res 1994;54:3506-10.
39. McQuire W, Rowinsky E, Rosenshein N. Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial Neoplasms. Ann Intern Med 1989;111:273-9.
40. Aisner J, Albain K, Belani C, Bunn P, Choy H, Glantz M et al. Taxol (paclitaxel) Clinical Experience in an Outpatient Setting. Bristol-Myers Squibb Co, Princeton NJ, 1994.
41. 90Yttrium-labeled Chimeric L6 Antibody:Efficacy and Toxicity in Breast Cancer Xenografts. Proc Natl Acad Sci 1997;94:4000-4.
42. Geard C, Jones J, Schiff P. Taxol and Radiation. J Natl Cancer Inst Monogr 1993;15:89-94.
43. Choy H, Akerley W. Paclitaxel, carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer. Oncology 1998;12(1 Suppl 2): 80-6.
44. Steren A, Sevin B, Perras J, Angioli R, Nguyen H, Guerra L et al. Averette. Taxol Sensitizes Human Ovarian Cancer Cells to Radiation. Gynecol Oncol 1993;48:252-8.